Evidence map›Paper›PMID 38642927›Full record

ArticleRMD open2024

Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology.

Yaëlle R Besten, Laura Boekel, Maurice Steenhuis, Femke Hooijberg, Sadaf Atiqi, Maureen Leeuw, Erik H Vogelzang, Jim Keijser, Sofie Keijzer, Floris C Loeff and 5 more

Open access · goldAbstract read
In one paragraph

Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Yaëlle R BestenRheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands.
Laura BoekelRheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands l.boekel@reade.nl.ORCID 0000-0001-5473-7786
Maurice SteenhuisImmunopathology, Sanquin Diagnostic Services, Amsterdam, Netherlands.
Femke HooijbergRheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands.
Sadaf AtiqiRheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands.
Maureen LeeuwRheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands.
Erik H VogelzangMedical Microbiology and Infection Control, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands.
Jim KeijserImmunopathology, Sanquin Diagnostic Services, Amsterdam, Netherlands.
Sofie KeijzerImmunopathology, Sanquin Diagnostic Services, Amsterdam, Netherlands.
Floris C LoeffImmunopathology, Sanquin Diagnostic Services, Amsterdam, Netherlands.
Martijn GerritsenRheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands.
Sander W TasDepartment of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, University of Amsterdam, Amsterdam, Netherlands.
Michael T NurmohamedRheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands.ORCID 0000-0002-6274-1934
Theo RispensImmunopathology, Sanquin Diagnostic Services, Amsterdam, Netherlands.
Gertjan WolbinkRheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands.
Reade · NLSanquin · NLBiology of Infection · FRUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring the COVID-19 pandemic, we developed a digital research platform to longitudinally investigate COVID-19-related outcomes in patients with rheumatic diseases and healthy controls. We used home finger-prick testing in order to collect serum samples remotely and increase the overall efficiency of the platform. The aim of the present study was to evaluate the success rate of the finger prick and patients' perspective towards the finger prick.

methodsSerum samples were collected up to five times during follow-up, either via a venepuncture at the research institute or a finger prick from participants' home. Participants were asked to complete a digital evaluation questionnaire of the finger prick after their attempts.

resultsA total of 2135 patients and 899 controls performed at least one finger prick and were included in this study. The first finger prick was successfully done by 92% (95% CI: 90% to 93%) of patients, 94% (95% CI: 92% to 95%) of controls, 93% (95% CI: 92% to 94%) of all participants aged ≤70 years and 89% (95% CI: 86% to 92%) of all participants aged >70 years. Sex did not impact these success rates. Repeated failure occurred in 11/439 (0.8%) patients and 4/712 (0.6%) controls. Both patients and controls were less willing to perform a finger prick for individual healthcare compared with scientific research.

conclusionThe vast majority of participants, among which elderly and patients with rheumatic diseases, were able to successfully draw the required amount of blood for serological analyses. This shows that finger-prick testing is suitable for a high-throughput implementation to monitor patients remotely.

Indexed as

COVID-19Rheumatic DiseasesRheumatologyAgedBlood Specimen CollectionFeasibility StudiesHumansPandemicsautoimmune diseasesCOVID-19epidemiology

Identifiers

PMID38642927
PMCPMC11033664
OpenAlexW4394976264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.